Vinva Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Vinva Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.67M	Buy	75,096 +369	+0.5%	+$49K	0.12%	178
2025 Q4	$10.5M	Buy	74,727 +67,951	+1,003%	+$9.84M	0.13%	156
2025 Q3	$950K	Buy	6,776 +1,691	+33%	+$229K	0.02%	325
2025 Q2	$638K	Buy	5,085 +336	+7%	+$38.5K	0.02%	339
2025 Q1	$537K	Sell	4,749 -8,542	-64%	-$1.08M	0.02%	324
2024 Q4	$1.82M	Sell	13,291 -25,249	-66%	-$3.12M	0.07%	236
2024 Q3	$4.43M	Buy	38,540 +21,795	+130%	+$2.99M	0.19%	126
2024 Q2	$2.25M	Buy	16,745 +10,266	+158%	+$1.41M	0.11%	191
2024 Q1	$894K	Buy	6,479 +1,678	+35%	+$229K	0.05%	299
2023 Q4	$634K	Buy	4,801 +650	+16%	+$74.8K	0.04%	311
2023 Q3	$478K	Sell	4,151 -1,063	-20%	-$112K	0.04%	299
2023 Q2	$493K	Sell	5,214 -9,215	-64%	-$900K	0.04%	306
2023 Q1	$1.43M	Buy	+14,429	New	+$1.5M	0.12%	196

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vinva Investment Management's NBIX Position: Q1 2026 in Review

Vinva Investment Management increased its Neurocrine Biosciences (NBIX) stake by 0.49% in Q1 2026, buying an estimated $49K and bringing the position to 75,096 shares worth $9.67M. The position accounts for 0.12% of the portfolio, ranked #178.

Vinva Investment Management first reported a position in NBIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $10.5M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Vinva Investment Management held 75,096 shares of Neurocrine Biosciences worth $9.67M as of Q1 2026.
Vinva Investment Management bought 369 Neurocrine Biosciences shares in Q1 2026, an estimated $49K.
Neurocrine Biosciences made up 0.12% of Vinva Investment Management's portfolio in Q1 2026, its #178 holding.
Vinva Investment Management first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 13 quarters since.
Vinva Investment Management's Neurocrine Biosciences position peaked at $10.5M in Q4 2025.
696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Vinva Investment Management's 13F filing for Q1 2026, filed 14 May 2026.